Work

Capmatinib plus osimertinib versus platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIb/IIIc or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps9153

Authors: Yi-Long Wu, Ji-Youn Han, Terufumi Kato, Fabrice Barlesi, Edward B. Garon, Federico Cappuzzo, Yuji Shibata, Nathalie Smith, Sadhvi Khanna, Riccardo Belli, Alejandro Javier Yovine, Daniel S.W. Tan

Institutions: Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, National Cancer Center, National Cancer Center Hospital, Kanagawa Cancer Center, Institut Gustave Roussy, Fondation Gustave Roussy, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, Instituto Nazionale Tumori Regina Elena, National Cancer Center Hospital East, Novartis (Switzerland), Novartis (France), National Cancer Centre Singapore

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281698658

Cites:

Cited by: 8

Related to: 10